Great to see the feedback from several people on this list with interesting references.
Charlie, Eric and Michel I strugle a bit with setup of HCLS-IG calls. Could this be a topic on a coming call? Given the vacation period and the deadline for response, 5th Oct, do you think this is doable? Regards Kerstin 15 aug 2012 kl. 08:01 skrev "Mead, Charlie (NIH/NCI) [C]" <mea...@mail.nih.gov>: > I would say Yes -- particularly since there is now an effort to represent > some of newest HL7 standards -- FHIR resource definitions in particular -- > using SW approaches...and the BRIDG OWL representation will almost certainly > benefit from this effort. > > charlie > ________________________________________ > From: Kerstin Forsberg [kerstin.l.forsb...@gmail.com] > Sent: Wednesday, August 15, 2012 1:57 AM > To: HCLS hcls > Subject: FDA: seeks input on Study Data Exchange Standards > > FDA seeks "input from industry, technology vendors, and other members of the > public regarding the advantages and disadvantages of current and emerging > open, consensus-based standards for the exchange of regulated study data. " > > In the annoncement for a meeting 5 November FDA ask for responses, before 5 > October, on questions such as "- What are the advantages and disadvantages of > HL7 v3 and CDISC ODM?" > > And, interestingly, they also ask: "- Are there other open data exchange > standards that should be evaluated?" > > Is this an opportunity for a semantic web based proposal? > > Kind Regards > > Kerstin Forsberg > > AstraZeneca > > > > https://www.federalregister.gov/articles/2012/08/14/2012-19748/regulatory-new-drug-review-solutions-for-study-data-exchange-standards-notice-of-meeting-request-for